We found that, in tumor tissue, RNase A treatment alters the expression of genes involved in metabolic pathways (25.1%), cancer-related events (responsible for cell growth, modulation of the cancer microenvironment and extracellular matrix components [17.9%]), pathways responsible for cell growth promoting and transforming activity (25.4%), transcription regulation (23.5%), tumor inductors and suppressors (6.2%), and miRNA-processing machinery (1.6%) (Table 1 and Supplementary Tables 1 –4). The gene discussed is RNASE1; the disease is neoplasm.